Table 2 Clinical responses in VIN patients treated by imiquimod and TA-CIN

	Lesion size in mm				Histology				HPV type				Symptoms
Patient no.	Wk 0	Wk 10	Wk 20	Wk 52	Wk 0	Wk 10	Wk 20	Wk 52	Wk 0	Wk 10	Wk 20	Wk 52	Wk 0	Wk 10	Wk 20	Wk 52
1δ	80	35	30	40	VIN1/2/3	VIN1/2/3	VIN2/3	VIN2/3	Neg	Neg	16	16	Mild	Moderate	Mild	Moderate
2δ	75	60	70	70	VIN3	VIN1/2/3	VIN2/3	VIN2/3	16	16	16	16	Severe	Moderate	Moderate	Severe
3	90	65	40	30	VIN2/3	VIN2/3	VIN2/3	VIN1/2	42	Neg	Neg	Neg	Moderate	Severe	Mild	Mild
4δ	50	40	30	45	VIN2/3	VIN2/3	VIN2/3	VIN2/3	16	16	16	Neg	Severe	Moderate	Mild	Mild
9	>100	25	20	10	VIN3	VIN2/3	VIN2/3	VIN2/3	16	16	16	16	Severe	Moderate	Mild	Mild
16φ	45	20	30	40	VIN2/3	VIN2/3	VIN2/3	VIN2/3	16	16	16	16	Severe	Severe	Severe	Severe
18	30	20	10	20	VIN2/3	VIN2/3	VIN2/3	VIN2/3	16	16	16	16	Mild	Mild	Mild	Mild
5	60	10	0	0	VIN1/2/3	No VIN	No VIN	No VIN	16	Neg	Neg	Neg	Mild	Moderate	None	None
6	65	25	5	0	VIN2/3	No VIN	No VIN	No VIN	16	16	Neg	16,53	Severe	Mild	None	None
7χ	100	50	50	0	VIN3	No VIN	No VIN	No VIN	16,33,84	Neg	N/E	33	Severe	Mild	Mild	Mild
8α	60	25	25	25	VIN2/3	VIN2/3	VIN2	No VIN	16	16,33,81	N/E	16	Severe	Severe	Severe	Severe
10δ	25	10	0	0	VIN2/3	VIN1/2/3	No VIN	No VIN	Neg	Neg	Neg	Neg	Severe	None	None	Mild
11	25	0	0	0	VIN3	No VIN	No VIN	No VIN	Neg	Neg	84	84	Moderate	Moderate	None	None
12	20	0	0	0	VIN3	VIN1/2	No VIN	No VIN	Neg	33	Neg	16,33	Moderate	Moderate	None	None
13	50	40	20	0	VIN3	VIN1/2	No VIN	No VIN	16	16	16	16	None	Mild	None	None
14β	90	15	15	0	VIN2/3	VIN1/2	No VIN	No VIN	16	Neg	Neg	Neg	Moderate	None	Moderate	Mild
15	25	3	0	0	VIN3	No VIN	No VIN	No VIN	16	Neg	16	Neg	Severe	None	None	None
17α	40	3	4	0	VIN2	VIN1/2	No VIN	No VIN	16	Neg	16	16	Moderate	Moderate	Moderate	Mild
19	>100	0	0	0	VIN2/3	No VIN	No VIN	No VIN	16	Neg	6	6	Severe	Mild	Mild	None

Abbreviations: HPV=human papillomavirus; CIN=cervical intraepithelial neoplasia; Neg=negative; N/E=non-evaluable; VIN2/3=vulval intraepithelial neoplasia grades 2 and 3; wk=week.
Patient 7 developed ESI (χ) at week 30; patients 1, 2, 4 and 10 underwent LASER treatment (δ) after trial completion; patient 14 developed recurrence (β) 6 months after trial completion and underwent LASER and surgery. Patients 8 and 17 developed new lesions (α) after week 52 treated with LASER. Patient 16 repeated course of imiquimod (φ) after trial completion.

Search